Choose your sales office

News

ELITechGroup

Filter

Open filter menu
Reset
Reset

ELITechGroup Molecular inaugurates its new headquarter in Turin

Turin, 22nd December 2022 – ELITechGroup has inaugurated its new headquarters in Turin, becoming one of the largest molecular biology hubs in Europe. The inauguration was held on Friday 16th December in the presence of institutional figures, collaborators, and employees. At the ribbon cutting, Michela Favaro – Deputy Mayor of…
READ MORE

ELITechGroup’s Vitamin D reagents; ready-to-use chemistry for efficiency

Vitamin D is a fat-soluble steroid hormone that is required for the intestinal absorption of calcium, maintenance of calcium homeostasis, and protection against osteomalacia i.e. softening of the bones. Vitamin D deficiency can lead to loss of bone density which can contribute to osteoporosis (reduction in bone mass) and fractures…
READ MORE

ELITechGroup’s Cholinesterase – an economical option for low-volume testing

The primary role of Cholinesterase in Clinical Diagnostics is to detect or monitor an acquired or inherited pseudocholinesterase deficiency. Pseudocholinesterase deficiency is a condition that causes increased sensitivity to certain muscle relaxant drugs used during general anesthesia (choline esters). These drugs relax the muscles used for movement, including those used…
READ MORE

Our new Molecular MDR/MTB multiplex assay

Een high performance based on our MGB® technology: – MTB complex: M.tuberculosis, M.africanum, M.bovis, M.canetti, M.microti, M.caprae. – MGB resistence: Rifampicine en Izoniazide. – Ultra sensitive: 6CFU/ml! – Ready to use monoreagent. In combination with our RT-PCR Sample-to-Result ELITe InGenius the most flexible solution for the diagnosis of Tuberculosis. “
READ MORE

ELITechGroup and InfanDx AG to Collaborate on the Development and Manufacturing of HypoxE® Neonatal Care Test for Clinical Laboratories

HypoxE® Test allows for the early detection of Hypoxic-Ischemic Encephalopathy (HIE) caused by lack of oxygen during birth ELITechGroup to provide contract development and manufacturing services for HypoxE® IVD Tests designed for Selectra Pro family of clinical chemistry analyzers Chicago, IL, USA, July 27, 2022 – ELITechGroup and InfanDx AG…
READ MORE

ELITechGroup announces the launch of ELITe BeGenius®

ITALY, Torino, October 12th, 2021. It is with great satisfaction that ELITechGroup announces the launch of ELITe BeGenius®, the new CE-IVD stand-alone “Sample – to – Result” Real Time PCR solution. ELITe BeGenius® makes molecular biology universally accessible thanks to its compact footprint, exceptional ease-of-use, and total automation. Tailorable for…
READ MORE

ELITECHGROUP ACQUIRES GONOTEC, A LEADING MARKET PLAYER IN FREEZING POINT OSMOMETRY

  ELITechGroup, market leader in global vapor pressure osmometer technology, announces the acquisition of GONOTEC, a leading market player in freezing point osmometer technology. The purchase of the company unites two osmometry market leaders, providing the industry with a full range of osmometry solutions that meet specific needs enabling physicians…
READ MORE

Coronavirus (COVID 19): New CE-IVD Kit now available worldwide

ITALY, Torino, Mar, 03, 2020. ELITechGroup is pleased to announce the release of the GeneFinderTM COVID-19 Plus RealAmp Kit by OSANGHealthcare. The Kit is CE-IVD certified and detects SARS-CoV-2 on all major PCR cyclers as well as on the Sample-to Result-Platform ELITe InGenius® The test will complement the menu of…
READ MORE

New innovative molecular multiplex STI Plus assay

De ELITe MGB® STI PLUS Kit is the firtst CE-IVD multiplex RT-PCR test which is validated on a Sample-To-Result instrument; the ELITe InGenius® . In 1 single reaction 4 targets are detected: C. trachomatis, N. gonorrhoeae, M. genitalium, en T. vaginalis. De STI PLUS quadroplex test validated on the matrices…
READ MORE

Hospital Artificial Intelligence

Artificial intelligence (AI) is being utilized in many different walks of life these days to improve people’s lives. From vehicles that are able to drive themselves to smartphones that react to the commands people give them and provide them with the information they need, AI has come a long way…
READ MORE

New Heart Failure Treatment Possibility

The number of people suffering from heart failure is expected to increase almost 50 percent over the course of the next 15 years. This is very troubling because, as of right now, about half of those who suffer from heart failure die within five years of being diagnosed. Their heart…
READ MORE

Cystic Fibrosis Can Lead to Other Conditions

Macroduct Advanced and Baby
If you suffer from Cystic Fibrosis, then you already know the struggles associated with having the disease, but can CF lead to more? Recent studies have shown that it might. In a study published in the Cystic Fibrosis Journal, researchers were eager to determine the effects of Cystic Fibrosis and…
READ MORE